Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GRI BioGRI 28 Equity-to-Asset is 0.90 as of Jun. 2026, which is 53% above its 10-year median of 0.59. GuruFocus rates GRI with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,416 Biotechnology companies, GRI Bio ranks better than 90.04% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. GRI Bio's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $10.28 Mil. GRI Bio's Total Assets for the quarter that ended in Jun. 2026 was $11.38 Mil.
The historical rank and industry rank for GRI Bio's Equity-to-Asset or its related term are showing as below:
GRI'
s Equity-to-Asset Range Over the Past 10 Years
Min: -21.67 Med: 0.59 Max: 0.93
Current: 0.93
During the past 5 years, the highest Equity to Asset Ratio of GRI Bio was 0.93. The lowest was -21.67. And the median was 0.59.
GRI's Equity-to-Asset is ranked better than 90.04% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs GRI: 0.93
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
GRI Bio Equity-to-Asset Related Terms
GRI Bio Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for GRI Bio's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRI vs ISCO, VRAX, SLXN: Equity-to-Asset Comparison
For the Biotechnology subindustry, GRI Bio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GRI Bio Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GRI Bio's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where GRI Bio's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
GRI Bio's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRI Bio (GRI) has a Equity-to-Asset of 0.90 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on GRI Bio and its competitors. This is 53% above median its historical median of 0.59. According to the industry distribution chart, GRI Bio ranks #141 out of 1416 companies in the Biotechnology industry, placing it in the top 10%.
Is GRI Bio's Equity-to-Asset too high?
GRI Bio's current Equity-to-Asset of 0.90 is 53% above median its 10-year median of 0.59. The Biotechnology industry median Equity-to-Asset is 0.68. GRI Bio's value of 0.90 is 32.4% above this industry median. Based on the distribution chart, GRI Bio ranks #141 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, GRI Bio has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does GRI Bio's Equity-to-Asset compare to ISCO and VRAX?
According to the Biotechnology industry distribution chart, GRI Bio ranks #141 out of 1416 companies for Equity-to-Asset. This places GRI Bio in the top 10% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. GRI Bio's value of 0.90 is 32.4% above this benchmark. While the company's 10-year median is 0.59 vs. the industry median of 0.68, GRI Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GRI Bio's current Equity-to-Asset of 0.90 is 32.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on GRI Bio and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GRI Bio's current Equity-to-Asset is 0.90, which is 53% above median its own 10-year median of 0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GRI Bio stock overvalued right now?
GRI Bio (GRI) has a current Equity-to-Asset of 0.90. The current Equity-to-Asset is 0.90, which is 53% above median its 10-year median of 0.59 and 32.4% above the Biotechnology industry median of 0.68. GRI Bio's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For GRI Bio (GRI), the current Equity-to-Asset is 0.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
28GF Score
Get the complete analysis for GRI
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRI has been successfully added to your 
